Tyra Biosciences, Inc. - 10-Q Filing

Tyra Biosciences reports third quarter 2025 financial results with continued investment in Dabogratinib clinical programs.

SEC EDGAR ·

Tickers: $TYRA

Read the full article at SEC EDGAR

More Regulatory news